English, Article, Journal or magazine article edition: The Nature and the Extent of the Market for Technology in Biopharmaceuticals Arora, Ashish; Gambardella, Alfonso; Pammolli, Fabio; ...

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/97236
Physical Description
  • preprint
Language
  • English

Edition details

Title
  • The Nature and the Extent of the Market for Technology in Biopharmaceuticals
Author
  • Arora, Ashish
  • Gambardella, Alfonso
  • Pammolli, Fabio
  • Riccaboni, Massimo
Physical Description
  • preprint
Notes
  • This paper explored an unusually comprehensive dataset of more than 2,000 drug R&​D projects all over the world during the 1990s. This enabled us to characterise several features of the innovation process in pharmaceuticals, particularly the different role and comparative R&​D performance of the large established drug companies vis-à-vis smaller high-tech specialist firms - the so-called New Biotechnology Firms (NBFs). Our results can be summarised as follows: a)The NBFs are largely an American phenomenon. More than half of the drug R&​D projects originated in the US are by NBFs, while almost 90% of the drug R&​D projects originated in Europe are from established pharmaceutical firms; b)Collaborative R&​D projects are consistently more likely to occur in the US than in Europe. However, in-house projects are a significant majority of the drug R&​D projects that entered the clinical stages. c)The established pharmaceutical companies have comparative advantages with respect to the NBFs in drug development (clinical trials). In drug discovery there is no advantage related to scale. Unlike clinical developments, where the large firms seem to have superior capabilities when compared to the NBFs, in discovery there is no inherent superiority (in terms of ultimate probability of success of the compounds) of either the NBFs or the large firms. d)The NBFs are not specialized in more risky R&​D projects. In fact, more risky drug projects (i.e. drugs for which there is no or there are few existing remedies) are more likely to be undertaken by the larger pharmaceutical companies. This suggests that scale, market power, and the ability to moblise large amounts of resources are key factors in enabling the firms to sustain such higher risks. e)Other things being equal, the projects originated by the NBFs are more likely to fail in the earlier clinical stages. This suggests that the NBFs perform a good deal of exploration without incurring the higher costs of failing at later stages.
  • Innovation; Markets for technology; Biopharmaceutical Industry; R&​D Collaboration
  • RePEc:pra:mprapa:15977
Language
  • English
Contributed by
OAIster

Get this edition

Other links

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment